Rapid Micro Biosystems (RPID)
NASDAQ:RPID
Want to see RPID full AI Analyst Report?
RPID Stock Chart & Stats
$2.28
-$0.03(-2.88%)
At close: 4:00 PM EST
$2.28
-$0.03(-2.88%)
Day’s Range― - ―
52-Week Range$1.76 - $4.94
Previous CloseN/A
Volume19.55K
Average Volume (3M)253.56K
Market Cap
$93.67M
Enterprise Value$100.99M
Total Cash (Recent Filing)$22.95M
Total Debt (Recent Filing)$23.71M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jul 31, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,322,280
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit23.68
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$6.67Price Target Upside192.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$39.25M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue BaseRecurring revenue representing 63% of sales creates annuity-like cash flow from consumables and service contracts tied to the installed base. This structural mix improves revenue visibility, supports higher lifetime customer value, and enables margin leverage as usage scales.
MilliporeSigma PartnershipAn exclusive collaboration with MilliporeSigma materially extends distribution, validation capabilities and potential supply agreements. Structurally this can expand addressable markets, accelerate customer validation cycles, and improve consumable sourcing and unit economics long-term.
Installed Base GrowthA growing installed base (196 systems) and enterprise multi-system orders provide reproducible demand for consumables and services. Large-customer adoption creates reference sites and durable commercial momentum that supports recurring revenue growth and margin expansion over time.
Bears Say
Cash Burn & Liquidity RiskSustained negative operating and free cash flow forces dependence on external financing; recent $15M Q1 burn and conditional credit tranches elevate funding and execution risk. Continued cash deficits raise the probability of dilution or covenant constraints absent operating improvement.
Rising LeverageMaterial increase in leverage from an eroding equity base reduces financial flexibility and raises interest/covenant exposure. High leverage combined with deep losses magnifies downside risk and limits the company's ability to absorb operational setbacks or finance growth without dilutive capital.
Low & Variable Gross MarginsDespite improvements, absolute gross margins remain weak and service margin is volatile due to validation timing. High full-year OpEx guidance means profitability hinges on sustained margin recovery and conversion of the sales funnel, creating structural execution risk.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
Rapid Micro Biosystems lowest stock price was $1.76 and its highest was $4.94 in the past 12 months.
What is Rapid Micro Biosystems’s market cap?
Rapid Micro Biosystems’s market cap is $93.67M.
When is Rapid Micro Biosystems’s upcoming earnings report date?
Rapid Micro Biosystems’s upcoming earnings report date is Jul 31, 2026 which is in 47 days.
How were Rapid Micro Biosystems’s earnings last quarter?
Rapid Micro Biosystems released its earnings results on May 13, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.063.
Is Rapid Micro Biosystems overvalued?
According to Wall Street analysts Rapid Micro Biosystems’s price is currently Undervalued.
Does Rapid Micro Biosystems pay dividends?
Rapid Micro Biosystems does not currently pay dividends.
What is Rapid Micro Biosystems’s EPS estimate?
Rapid Micro Biosystems’s EPS estimate is -0.24.
How many shares outstanding does Rapid Micro Biosystems have?
Rapid Micro Biosystems has 45,322,280 shares outstanding.
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Rapid Micro Biosystems reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
Currently, no hedge funds are holding shares in RPID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapid Micro Biosystems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (192.40% Upside)
$6.67 (192.40% Upside)
Blogger Sentiment
Bullish
RPID Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $147.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.67%
12-Months-Change
Fundamentals
Return on Equity
-131.52%
Trailing 12-Months
Asset Growth
-27.00%
Trailing 12-Months
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
RPID Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but improving picture: revenue, product/consumables growth, recurring revenue expansion, system placements, and a strategic MilliporeSigma partnership are meaningful positives and support long-term margin improvement. However, near-term challenges include low absolute gross margins, a widened net loss, elevated operating expenses, significant Q1 cash burn, and variability in service revenue tied to validation timing. Management reiterated full-year revenue guidance and outlined margin improvement expectations, but execution risk and liquidity depend on achieving planned cost reductions, converting the sales funnel (including MilliporeSigma-driven placements), and unlocking credit facility tranches.View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
$6.67
▲(192.40% Upside)
Technical Analysis
Ownership Overview
33.01% Insiders
2.60% Mutual Funds
28.12% Other Institutional Investors
33.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---